Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research/Financing Note: Ultragenyx Pharmaceutical (RARE) priced offering of 7,435,898 shares at $39.00 per share.

June 14, 2024

RARE closed down -$1.52 at $43.12 with a -$1.94 or -4.50% to $41.18 The offering is expected to close on or about 6/17/24, subject to satisfaction of customary closing conditions.  J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the offering.  

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results

May 20, 2024

A scorecard of earnings releases of covered companies -  The current LPS (loss per share) or net income, revenue, cash positions i.e. "runways" is a reflection of this universe's investing "status". 30 of 35    

RegMed Investors (RMi) Research Note: Q1/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes

May 7, 2024

LPS (loss-per-share) releases will present challenges to share pricing with outcomes included 17 reported so far <RGNX, CRSP, LENZ, CRBU, VCEL, VERV, EDIT, AGEN, IONS, QURE, BEAM, SAGE, MDXG, ALNY, BPMC, AXGN, RARE)